|
1
|
Field JK, Oudkerk M, Pedersen JH and Duffy
SW: Prospects for population screening and diagnosis of lung
cancer. Lancet. 382:732–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curioni-Fontecedro A, Husmann L, Soldini D
and Stahel RA: Primary non-small cell lung cancer response upon
treatment with denosumab. Lung Cancer. 82:506–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Navarro A, Diaz T, Gallardo E, et al:
Prognostic implications of miR-16 expression levels in resected
non-small-cell lung cancer. J Surg Oncol. 103:411–415. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vosa U, Vooder T, Kolde R, Vilo J,
Metspalu A and Annilo T: Meta-analysis of microRNA expression in
lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chitwood DH and Timmermans MC: Small RNAs
are on the move. Nature. 467:415–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bowen T, Jenkins RH and Fraser DJ:
MicroRNAs, transforming growth factor beta-1, and tissue fibrosis.
J Pathol. 229:274–285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo Z, Dai Y, Zhang L, et al: miR-18a
promotes malignant progression by impairing microRNA biogenesis in
nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Yu X, Guo X, et al: miR-143 is
downregulated in cervical cancer and promotes apoptosis and
inhibits tumor formation by targeting Bcl-2. Mol Med Rep.
5:753–760. 2012.PubMed/NCBI
|
|
13
|
Yoshida K, Saito T, Kamida A, et al:
Transforming growth factor-beta transiently induces vimentin
expression and invasive capacity in a canine mammary gland tumor
cell line. Res Vet Sci. 94:539–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong L, Ge XY, Wang YX, et al:
Transforming growth factor-beta and epithelial-mesenchymal
transition are associated with pulmonary metastasis in adenoid
cystic carcinoma. Oral Oncol. 49:1051–1058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian M, Neil JR and Schiemann WP:
Transforming growth factor-beta and the hallmarks of cancer. Cell
Signal. 23:951–962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choe C, Shin YS, Kim SH, et al:
Tumor-stromal interactions with direct cell contacts enhance
motility of non-small cell lung cancer cells through the hedgehog
signaling pathway. Anticancer Res. 33:3715–3723. 2013.PubMed/NCBI
|
|
17
|
Huang S, Holzel M, Knijnenburg T, et al:
MED12 controls the response to multiple cancer drugs through
regulation of TGF-beta receptor signaling. Cell. 151:937–950. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Argast GM, Krueger JS, Thomson S, et al:
Inducible expression of TGFbeta, snail and Zeb1 recapitulates EMT
in vitro and in vivo in a NSCLC model. Clin Exp Metastasis.
28:593–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tai J, Xiao X, Huang ZG, et al: MicroRNAs
regulate epithelial-mesenchymal transition of supraglottic
laryngeal cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
48:499–503. 2013.(In Chinese).
|
|
20
|
Peng X, Guo W, Liu T, et al:
Identification of miRs-143 and -145 that is associated with bone
metastasis of prostate cancer and involved in the regulation of
EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boominathan L: The tumor suppressors p53,
p63, and p73 are regulators of microRNA processing complex. PLoS
One. 5:e106152010. View Article : Google Scholar
|
|
22
|
Davis-Dusenbery BN, Chan MC, Reno KE, et
al: Down-regulation of Kruppel-like factor-4 (KLF4) by
microRNA-143/145 is critical for modulation of vascular smooth
muscle cell phenotype by transforming growth factor-beta and bone
morphogenetic protein 4. J Biol Chem. 286:28097–28110. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YY, Ren T, Cai YY and He XY: MicroRNA
let-7a inhibits the proliferation and invasion of nonsmall cell
lung cancer cell line 95D by regulating K-Ras and HMGA2 gene
expression. Cancer Biother Radiopharm. 28:131–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi L, Campbell G, Jones WD, et al: The
MicroArray Quality Control (MAQC)-II study of common practices for
the development and validation of microarray-based predictive
models. Nat Biotechnol. 28:827–838. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gordon KJ and Blobe GC: Role of
transforming growth factor-beta superfamily signaling pathways in
human disease. Biochim Biophys Acta. 1782:197–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao W, Yu Y, Cao H, et al: Deregulated
expression of miR-21, miR-143 and miR-181a in non small cell lung
cancer is related to clinicopathologic characteristics or patient
prognosis. Biomed Pharmacother. 64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma Q, Jiang Q, Pu Q, et al: MicroRNA-143
inhibits migration and invasion of human non-small-cell lung cancer
and its relative mechanism. Int J Biol Sci. 9:680–692. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Y, Ou Y, Wu K, Chen Y and Sun W:
miR-143 inhibits the metastasis of pancreatic cancer and an
associated signaling pathway. Tumour Biol. 33:1863–1870. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Zhang SZ, Cai SR, Peng JP and Zheng
S: Effect of microRNA143 expression on cell proliferation in
colonic carcinoma. Zhonghua Zhong Liu Za Zhi. 30:498–501. 2008.(In
Chinese).
|
|
32
|
Tabyaoui I, Tahiri-Jouti N, Serhier Z, et
al: Immunohistochemical expression of CD44s in human neuroblastic
tumors: Moroccan experience and highlights on current data. Diagn
Pathol. 8:392013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hiraga T, Ito S and Nakamura H: Cancer
stem-like cell marker CD44 promotes bone metastases by enhancing
tumorigenicity, cell motility, and hyaluronan production. Cancer
Res. 73:4112–4122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raso-Barnett L, Banky B, Barbai T, Becsagh
P, Timar J and Raso E: Demonstration of a melanoma-specific CD44
alternative splicing pattern that remains qualitatively stable, but
shows quantitative changes during tumour progression. PLoS One.
8:e538832013. View Article : Google Scholar
|
|
35
|
Zeller E, Hammer K, Kirschnick M and
Braeuning A: Mechanisms of RAS/beta-catenin interactions. Arch
Toxicol. 87:611–632. 2013. View Article : Google Scholar
|
|
36
|
Sawaki D and Suzuki T: Targeting
transforming growth factor-beta signaling in aortopathies in Marfan
syndrome. Circ J. 77:898–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jakobsson L and van Meeteren LA:
Transforming growth factor beta family members in regulation of
vascular function: in the light of vascular conditional knockouts.
Exp Cell Res. 319:1264–1270. 2013. View Article : Google Scholar : PubMed/NCBI
|
